Taken together, our pharmaceutical data suggest that it is feasible to develop a kisspeptin medical product for nasal delivery (in solution or powder) that is easily self-administered by patients at home, similar to the well-established clinically used intranasal desmopressin for diabetes insipidus (arginine vasopressin deficiency). This evidence concerns the gene KISS1 and Central diabetes insipidus.